



Martin Fitchet, M.D.
Global Therapeutic Area Head, Pulmonary Hypertension

Martin Fitchet, M.D. is Global Head of R&D at Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson, and Global Therapeutic Area (TA) Head, Pulmonary Hypertension at Janssen.

In this role, effective October 2017, he is responsible for all aspects of Actelion's Research & Development strategy and execution across its growing portfolio of assets in Pulmonary Arterial Hypertension and beyond. In addition, he acts as Global TA Head, Pulmonary Hypertension, which Janssen R&D added to its existing portfolio of Therapeutic Areas.

Martin joined Actelion from Johnson & Johnson Medical Devices, where he has been leading global Research & Development across the company's three Medical Devices franchises – DePuy Synthes, Ethicon and Cardiovascular & Specialty Solutions. Prior to that, Martin served as Global Head of Research & Development for the DePuy Synthes Companies of Johnson & Johnson since 2014. During his tenure, he oversaw new product development, aligned and prioritized innovation platforms, and jointly with his team strengthened portfolio prioritization, productivity, launch cadence and portfolio value for global orthopaedics.

First joining Johnson & Johnson in 2000, Martin assumed positions of increasing responsibility including Chief Operating Officer for Janssen R&D, where he oversaw operational excellence and execution of clinical development programs, thereby maximizing effectiveness and efficiency in bringing new medicines to patients. As Global Therapeutic Area Head for Cardiovascular & Metabolism R&D, he was responsible for the development of compounds in cardiovascular disease and diabetes including XARELTO® and INVOKANA®. Prior to Johnson & Johnson, he held scientific leadership positions in Medical Affairs and Research & Development in metabolism and diabetes for Sanofi Aventis and Novartis.

Having earned his degree at the University of Nottingham Medical School, UK, Martin became a Fellow of the Royal College of Surgeons of England in 1995, and joined the Faculty of Pharmaceutical Medicine in London, UK.